Related Experiment Videos
STI571: a paradigm of new agents for cancer therapeutics
Michael J Mauro1, Michael O'Dwyer, Michael C Heinrich
1Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd., Portland, OR 97201, USA.
Abstract:
STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.
Insights
STI571 is a targeted therapy for chronic myelogenous leukemia (CML). It works by inhibiting the Bcr-Abl protein, offering a successful example of rational drug design for cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is characterized by the Bcr-Abl fusion protein.
- Targeting specific molecular abnormalities offers a promising therapeutic strategy.
Purpose of the Study:
- To review the development of STI571 (imatinib) as a targeted therapy for CML.
- To explore challenges in clinical trials for molecularly targeted agents.
- To discuss potential applications in other cancers and resistance mechanisms.
Main Methods:
- Review of scientific literature on STI571 development.
- Analysis of Bcr-Abl as a therapeutic target.
- Discussion of clinical trial parameters and resistance.
Main Results:
- STI571 (imatinib) represents a successful rationally designed molecularly targeted therapy.
- Identification and targeting of Bcr-Abl abnormality in CML.
- Exploration of dose selection, response prediction, and resistance.
Conclusions:
- STI571 exemplifies a successful paradigm for targeted cancer therapy.
- The approach has potential for treating other malignancies.
- Understanding resistance mechanisms is crucial for optimizing therapy.